Innovating Works

GAADRD

Desconocido
2D-BioPAD: Supple Graphene Bio Platform for point of care early detection and monitoring of Alzheimer s Disease ELLINIKI ETAIRIA NOSOY ALZHEIMER KAI SYGGENON DIATARACHON SOMATEIO participó en un HORIZON EUROPE: HORIZON-CL4-2022-DIGITAL-EMERGING-02 2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Al...
2023-06-29 - 2027-09-30 | Financiado
RECAGE: How to best meet the needs of people with dementia with severe behavioural disturbances. Toward a re... The RECAGE project will tackle one of the most challenging problem arising during the clinical course of dementia: the so-called Behavioural...
2017-11-15 - 2023-06-30 | Financiado
ehcoBUTLER: ehcoBUTLER. A global ecosystem for the independent and healty living of elder people with mild cogni... ELLINIKI ETAIRIA NOSOY ALZHEIMER KAI SYGGENON DIATARACHON SOMATEIO participó en un H2020: H2020-PHC-2014-2015 The ehcoBUTLER Idea: Nowadays, it is a fact that Europe is ageing. A common characteristic of elders is the frequent occurrence of either ph...
2014-12-05 - 2022-03-31 | Financiado
PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... ELLINIKI ETAIRIA NOSOY ALZHEIMER KAI SYGGENON DIATARACHON SOMATEIO participó en un FP6: PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
2010-01-01 - 2015-12-31 | Financiado
PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... ELLINIKI ETAIRIA NOSOY ALZHEIMER KAI SYGGENON DIATARACHON SOMATEIO participó en un FP7: PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.